Eli Lilly (LLY +0.28%) is trying to turn blockbuster obesity drugs into something much bigger. Its path to $1,500 depends on whether new medicines, additional indications, manufacturing scale, and rising patient volumes can generate durable earnings sufficient to overcome pricing pressure and a demanding valuation.
Stock prices used were the market prices of Sept. 15, 2026. The video was published on Oct. 7, 2026.





